Announcement PDF ASX Announcement 11 October 2023 PHASE III CLINICAL TRIAL INVESTOR WEBINAR Melbourne, Australia, 11 October 2023: Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) is pleased to announce it will hold an investor webinar for shareholders and all other interested parties to provide more detail on its pivotal Phase III clinical trial testing the Company’s proprietary TPM® enhanced CBD soft-gel capsule’s ability to manage the symptoms of insomnia. CEO, Dr Paul Gavin, will present at 11.00am (AEDT) on Friday 13 October 2023. Register to attend the presentation at the following link: https://us02web.zoom.us/webinar/register/WN_srQ9CclRQG6ywB0JPpkEmw A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company’s website, InvestorHub platform and social media channels. Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au. For enquiries, please contact Dr Paul Gavin Chief Executive Officer Avecho Biotechnology Limited +61 3 9002 5000 This announcement has been authorised by the Chief Executive Officer of Avecho Biotechnology Limited. About Avecho Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients. Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock. See more here - avecho.com.au Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403 Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168 3440-6518-1734, v. 1 avecho.com.au